)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
MediciNova
MediciNova (MNOV) investor relations material
MediciNova Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
Focused on developing MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic/metabolic diseases, with a commercial focus on the U.S. market.
Accumulated deficit reached $443.6 million as of June 30, 2026, with expectations of continued net losses as development progresses.
Revenue growth in 2026 driven by clinical research services for Mayo Foundation ALS study.
Financial highlights
Revenues for Q2 2026 were $0.5 million, up from $0.1 million in Q2 2025, due to increased services for Mayo.
Net loss for Q2 2026 was $2.3 million, an improvement from $3.3 million in Q2 2025.
Six-month net loss was $4.9 million, improved from $6.1 million year-over-year.
Cash and cash equivalents totaled $25.4 million as of June 30, 2026.
Working capital stood at $23.0 million, sufficient to fund operations through at least November 2027.
Outlook and guidance
Expects to incur substantial net losses for several years as clinical programs advance.
Believes current cash resources are sufficient for at least the next 12 months.
Plans to pursue additional strategic alliances and non-dilutive financing to support development.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MediciNova
- Pivotal ALS and metabolic trials advance with strong funding and key data expected in 2026.MNOV
Corporate presentation - 2024 net loss increased to $11.0 million, with no product revenue and higher R&D expenses.MNOVQ4 2024
- Plans to raise up to $300M for clinical development of novel therapies in high-need areas.MNOVRegistration filing
- Q3 2024 net loss widened to $2.85 million as R&D costs rose and cash reserves fell to $42.3 million.MNOVQ3 2024
- Q1 2025 net loss was $2.86 million, with $36.6 million in cash and stable operating expenses.MNOVQ1 2025
- Annual meeting to vote on director, auditor, executive pay, and say-on-pay frequency; board favors 3 years.MNOVProxy filing
- Cash position supports operations through 2025 as net loss narrows and clinical programs advance.MNOVQ2 2024
- Shareholders will vote on director elections, auditor ratification, and a major share authorization increase.MNOVProxy filing
- Standby equity facility enables up to $30M in funding but poses dilution and volatility risks.MNOVRegistration filing
Next MediciNova earnings date
Q3 202611 Nov, 2026
MediciNova
Next MediciNova earnings date
Q3 202611 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage